CN106572994B - 含有乙内酰脲衍生物的药物组合物 - Google Patents

含有乙内酰脲衍生物的药物组合物 Download PDF

Info

Publication number
CN106572994B
CN106572994B CN201480079652.7A CN201480079652A CN106572994B CN 106572994 B CN106572994 B CN 106572994B CN 201480079652 A CN201480079652 A CN 201480079652A CN 106572994 B CN106572994 B CN 106572994B
Authority
CN
China
Prior art keywords
compound
bone
phenyl
cartilage
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480079652.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106572994A (zh
Inventor
野田宽
北村秀智
田村达也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN106572994A publication Critical patent/CN106572994A/zh
Application granted granted Critical
Publication of CN106572994B publication Critical patent/CN106572994B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480079652.7A 2014-06-09 2014-06-09 含有乙内酰脲衍生物的药物组合物 Active CN106572994B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/065262 WO2015189901A1 (ja) 2014-06-09 2014-06-09 ヒダントイン誘導体含有医薬組成物

Publications (2)

Publication Number Publication Date
CN106572994A CN106572994A (zh) 2017-04-19
CN106572994B true CN106572994B (zh) 2020-09-18

Family

ID=54833033

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480079652.7A Active CN106572994B (zh) 2014-06-09 2014-06-09 含有乙内酰脲衍生物的药物组合物
CN201580039807.9A Active CN106535892B (zh) 2014-06-09 2015-06-09 含有乙内酰脲衍生物的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580039807.9A Active CN106535892B (zh) 2014-06-09 2015-06-09 含有乙内酰脲衍生物的药物组合物

Country Status (10)

Country Link
US (1) US9993462B2 (enExample)
EP (1) EP3153166B1 (enExample)
KR (2) KR102266021B1 (enExample)
CN (2) CN106572994B (enExample)
AU (1) AU2014397042B2 (enExample)
BR (1) BR112016003511B8 (enExample)
CA (1) CA2949023C (enExample)
MX (1) MX371090B (enExample)
RU (1) RU2701168C2 (enExample)
WO (2) WO2015189901A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ707946A (en) * 2012-12-10 2019-11-29 Chugai Pharmaceutical Co Ltd Hydantoin derivative
US20210290541A1 (en) * 2018-07-30 2021-09-23 Chugai Seiyaku Kabushiki Kaisha Solid dispersion of hydantoin derivative
CN120418354A (zh) 2022-12-28 2025-08-01 中外制药株式会社 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433940A1 (en) * 2009-04-28 2012-03-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
CN104854106A (zh) * 2012-12-10 2015-08-19 中外制药株式会社 乙内酰脲衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
ATE305003T1 (de) 1998-12-11 2005-10-15 Hoffmann La Roche Zyklische hydrazinderivate als tnf-alpha inhibitoren
WO2002017911A1 (en) 2000-08-30 2002-03-07 Teijin Limited Parathyroid hormone production inhibitors containing vitamin d3 derivatives
AP2001002318A0 (en) 2000-10-26 2001-12-31 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
EP1713782A4 (en) 2004-02-11 2009-11-11 Smithkline Beecham Corp PTH AGONISTS
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
CA2582593A1 (en) * 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
WO2007149873A2 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DE602008003221D1 (de) * 2007-06-07 2010-12-09 Hoffmann La Roche Prolinamidderivate als nk3-antagonisten
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433940A1 (en) * 2009-04-28 2012-03-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
CN104854106A (zh) * 2012-12-10 2015-08-19 中外制药株式会社 乙内酰脲衍生物

Also Published As

Publication number Publication date
RU2016113896A3 (enExample) 2018-07-18
MX2016013684A (es) 2017-01-20
CN106535892B (zh) 2020-09-18
EP3153166A4 (en) 2018-01-17
AU2014397042A1 (en) 2016-02-11
KR20170010439A (ko) 2017-01-31
MX371090B (es) 2020-01-16
KR102266021B1 (ko) 2021-06-16
BR112016003511A8 (pt) 2018-01-30
CA2949023C (en) 2021-10-12
EP3153166A1 (en) 2017-04-12
WO2015190451A1 (ja) 2015-12-17
EP3153166B1 (en) 2022-08-03
US9993462B2 (en) 2018-06-12
KR102382331B1 (ko) 2022-04-01
CN106572994A (zh) 2017-04-19
BR112016003511A2 (enExample) 2017-08-01
WO2015189901A1 (ja) 2015-12-17
CA2949023A1 (en) 2015-12-17
RU2701168C2 (ru) 2019-09-25
AU2014397042B2 (en) 2020-04-09
US20170112812A1 (en) 2017-04-27
BR112016003511B1 (pt) 2022-11-08
KR20170010354A (ko) 2017-01-31
RU2016113896A (ru) 2018-07-18
BR112016003511B8 (pt) 2023-10-03
CN106535892A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
TW201623307A (zh) 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物
CN104854106B (zh) 乙内酰脲衍生物
JP2023502458A (ja) ピラゾロヘテロアリール系誘導体、その調製方法及びその医薬的応用
CN106572994B (zh) 含有乙内酰脲衍生物的药物组合物
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI686392B (zh) 含有乙內醯脲衍生物之醫藥組合物
JP6290138B2 (ja) ヒダントイン誘導体含有医薬組成物
HK1230945B (zh) 含有乙内酰脲衍生物的药物组合物
HK1229725B (zh) 含有乙内酰脲衍生物的药物组合物
HK1230945A1 (en) Hydantoin derivative-containing pharmaceutical composition
HK1229725A1 (en) Hydantoin derivative-containing pharmaceutical composition
HK1209735B (en) Hydantoin derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230945

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant